Rankings
▼
Calendar
PTCT Q3 2025 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
PTCT
PTC Therapeutics, Inc.
$6B
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$211M
+7.2% YoY
Gross Profit
$95M
45.1% margin
Operating Income
$3M
1.4% margin
Net Income
$16M
7.5% margin
EPS (Diluted)
$0.20
QoQ Revenue Growth
+18.0%
Cash Flow
Operating Cash Flow
-$66M
Free Cash Flow
-$70M
Stock-Based Comp.
$19M
Balance Sheet
Total Assets
$2.6B
Total Liabilities
$2.8B
Stockholders' Equity
-$156M
Cash & Equivalents
$673M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$211M
$197M
+7.2%
Gross Profit
$95M
$186M
-48.9%
Operating Income
$3M
-$55M
+105.5%
Net Income
$16M
-$107M
+114.9%
Revenue Segments
Product
$131M
62%
Royalty
$71M
34%
Collaboration and License Revenue
$9M
4%
Geographic Segments
Non-US
$75M
57%
UNITED STATES
$56M
43%
← FY 2025
All Quarters
Q4 2025 →